A Phase 1 Open Label Multi-Arm Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors

Brief description of study

This is a first-in-human (FIH), dose escalation, and dose finding trial to assess the safety and tolerability of MK-4830, both as monotherapy and as combination therapy with pembrolizumab.MK-4830 is a novel fully human monoclonal antibody (mAb) that is an antagonist of immunoglobulin-like transcript 4 (ILT4). The study drug MK-4830 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s19-01469
ClinicalTrials.gov Identifier: NCT03564691

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.